Document is current
Any future updates will be listed below
-
Authors
Andersen-Ranberg, Nina C. https://orcid.org/0000-0002-0804-1064
Poulsen, Lone Musaeus
Perner, Anders
Hästbacka, Johanna
Morgan, Matthew
Citerio, Giuseppe
Collet, Marie Oxenbøll
Weber, Sven-Olaf
Andreasen, Anne Sofie
Bestle, Morten
Uslu, Bülent
Pedersen, Helle Scharling
Nielsen, Louise Gramstrup
Damgaard, Kjeld
Jensen, Troels Bek
Sommer, Trine
Dey, Nilanjan
Mathiesen, Ole
Granholm, Anders
-
Funding
Funding for this research was provided by:
Regional Medicines Fund (R124-2651)
Innovationsfonden (4108-00011B)
Hindsgavl Intensiv Symposium
Fogts Foundation
- License Information
-
More Information
Article History
Received: 12 January 2023
Accepted: 28 February 2023
First Online: 27 March 2023
Declarations
:
: The Department of Intensive Care at Zealand University Hospital, Køge (NCAR, LMP, OM) has received funding for the AID–ICU trial from Innovations Fund Denmark, The Regional Medicines Fund, Zealand Region Research fund, Grosserer L.F. Foghts Fond and Hindsgavl Intensiv Symposium. The funding had no influence on the trial. The department conducts contract research for AM-Pharma, which is unrelated to this work. The Department of Intensive Care at Rigshospitalet (AP, MOC, AG) has received funding for other projects unrelated to this work from Sygeforsikringen “danmark”, The Novo Nordisk Foundation, Pfizer, and, Fresenius Kabi, and conducts contract research for AM-Pharma. The Department of Anaesthesiology and Intensive Care at Copenhagen University Hospital-North Zealand (MB) has received funding for other projects unrelated to this work from Sygeforsikring “danmark”, The Novo Nordisk Foundation, and conducted contract research for AM-Pharma and Inotrem. MB received consulting fees from AM-Pharma.
